Status:
TERMINATED
Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome
Lead Sponsor:
Fondation Ophtalmologique Adolphe de Rothschild
Conditions:
Covid19
SARS-CoV Infection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The COVID-19 pandemic has already overwhelmed the sanitary capacity. Additional therapeutic arsenals, albeit untested in the given context but previously proven to be efficacious in a related clinical...
Eligibility Criteria
Inclusion
- COVID-19 positive inpatient (PCR or other certified test mandatory)
- Inpatient showing at least one of the following criterion: Abnormal respiratory auscultation AND SpO2 \< 94% without oxygen therapy, OR Acute Respiratory failure requiring either oxygen therapy or high-flow oxygen therapy or non-invasive respirator and/or invasive respirator.
Exclusion
- Inpatient requiring legal protection
- Pregnant or breastfeeding woman
- Intensive care inpatient or patient undergoing surgery
- Secondary non inclusion criteria :
- \- Unintentional blinding removal.
Key Trial Info
Start Date :
April 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 15 2021
Estimated Enrollment :
31 Patients enrolled
Trial Details
Trial ID
NCT04341415
Start Date
April 9 2020
End Date
January 15 2021
Last Update
April 13 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Hospitalier Simone Veil
Beauvais, France, 60000
2
Fondation Adolphe de Rothschild
Paris, France, 75019